Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2025-12-25 @ 9:26 PM
Study NCT ID:
NCT05295056
Status:
COMPLETED
Last Update Posted:
2023-09-28
First Post:
2022-03-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Clinical Performance of the AFGen1 Device Over a 7-day Period
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001281', 'term': 'Atrial Fibrillation'}, {'id': 'D001145', 'term': 'Arrhythmias, Cardiac'}], 'ancestors': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 38}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-05-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-09', 'completionDateStruct': {'date': '2023-08-25', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-09-26', 'studyFirstSubmitDate': '2022-03-15', 'studyFirstSubmitQcDate': '2022-03-15', 'lastUpdatePostDateStruct': {'date': '2023-09-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-03-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-08-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Quantitative Evaluation', 'timeFrame': '7 days', 'description': 'For the quantitative evaluation of the mean and standard deviation of the QRS correlations for all study subjects and for the end of the wear period for those relevant subjects, the mean cor- relation coefficient must be greater than 0.95 and standard deviation must be less than 0.05 to validate a 95% confidence interval with significant factor of assurance.'}, {'measure': 'Qualitative Equivalence Evaluation', 'timeFrame': '7 days', 'description': 'For the qualitative equivalence evaluation according to the two cardiologists the confirmation of equivalence must be greater than 95%.'}, {'measure': 'Adhesive performance', 'timeFrame': '7 days', 'description': 'For the adhe sive performance element of the stud y; t he overall average wear time for the de- vice must be greater than 5 days'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Atrial Fibrillation', 'Afib', 'Irregular Heart Beat', 'Arrhythmias, Cardiac', 'Arrhythmia Atrial', 'Arrhythmias Paroxysmal', 'Paroxysmal Atrial Fibrillation']}, 'descriptionModule': {'briefSummary': 'AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of the AFib-Chek device (a.k.a. Device) on human participants.', 'detailedDescription': 'The primary purpose of this study is to demonstrate that the ECD signal acquired by the AFGen1 device is as of adequate quality and is suitable to support its intended use for the detection of AFib.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'maximumAge': '90 Years', 'minimumAge': '65 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'The study shall involve approximately 30-50 participants (approximately equal number of males and females, equal number with BMI \\< and \\> 35) meeting inclusion and exclusion criteria.', 'eligibilityCriteria': 'Inclusion Criteria:\n\n1\\. 18+ willing to sign the consent form\n\nExclusion Criteria:\n\n1. Implanted pacemakers\n2. Implanted cardioverter defibrillators\n3. Implanted cardiac resynchronization devices\n4. Potential life-threatening arrythmias\n5. Physical or mental health conditions that would prevent the person from being able to follow instruc-tions regarding participation in the study\n6. Open wounds, abraded or irritated skin at the application site\n7. Planned to undergo a MRI during the course of the study duration'}, 'identificationModule': {'nctId': 'NCT05295056', 'briefTitle': 'Clinical Performance of the AFGen1 Device Over a 7-day Period', 'organization': {'class': 'INDUSTRY', 'fullName': 'TriVirum, Inc.'}, 'officialTitle': 'Clinical Performance of the AFGen1 Device Over a 7-day Period', 'orgStudyIdInfo': {'id': 'AFib-Chek-001'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Permanent atrial fibrillation', 'description': 'Known to have permanent atrial fibrillation', 'interventionNames': ['Device: AFGen1 Device Wear Test']}, {'label': 'Healthy control', 'description': 'Healthy controls', 'interventionNames': ['Device: AFGen1 Device Wear Test', 'Device: AFGen 1 Device Single Use']}], 'interventions': [{'name': 'AFGen1 Device Wear Test', 'type': 'DEVICE', 'description': 'Participant wears the device for 7 days', 'armGroupLabels': ['Healthy control', 'Permanent atrial fibrillation']}, {'name': 'AFGen 1 Device Single Use', 'type': 'DEVICE', 'description': 'Participant wears the device in conjunction with a standard ECG', 'armGroupLabels': ['Healthy control']}]}, 'contactsLocationsModule': {'locations': [{'zip': '63123', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Clayton Sleep Institute', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'TriVirum, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}